TENAX THERAPEUTICS, INC. 8-K

What Happened
Tenax Therapeutics, Inc. (TENX) filed a Form 8-K on July 2, 2026 announcing a press release that it will present results from its Phase 3 LEVEL clinical trial in a Late‑Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. The company now expects to report topline data from the Phase 3 LEVEL trial in August 2026. The press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: July 2, 2026 (Form 8-K, Item 8.01: Other Events).
• Event: Presentation of Phase 3 LEVEL results in a Late‑Breaking Clinical Science session at ESC Congress 2026.
• Timing: Company expects to report topline Phase 3 LEVEL data in August 2026.
• Press release: Attached as Exhibit 99.1 to the 8-K.

Why It Matters
Phase 3 topline results are a major clinical and commercial milestone that can materially affect Tenax’s regulatory pathway, partnering prospects, and investor valuation. The planned August 2026 topline release provides a near‑term catalyst for the stock, and the Late‑Breaking presentation at ESC Congress 2026 signals the company views the data as noteworthy to the cardiology community. Investors should note the timing and monitor the actual topline announcement and full data when released.